15:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Reata reports retained benefit in Phase II CKD trial

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported Phase II data showing that chronic kidney disease (CKD) patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR) four weeks after discontinuing treatment. In 25 patients...
22:30 , Jul 23, 2018 |  BC Extra  |  Clinical News

Reata gains on retained benefit in CKD trial, proposes follow-on

Reata Pharmaceuticals Inc. (NASDAQ:RETA) added $30.15 (65%) to $76.55 on Monday after reporting Phase II data showing that chronic kidney disease patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR)...
19:05 , Jun 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest activating NFE2L2 could help treat ALS by promoting normal folding of mutant SOD1. Crystallographic analyses of an ALS-associated SOD1 mutant complexed with a library of cysteine-reactive...
17:17 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Reata reports Phase II data for omaveloxolone in mitochondrial myopathies

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported top-line data from the Phase II MOTOR trial in 53 patients with mitochondrial myopathies showing that omaveloxolone (oral RTA 408) missed the primary endpoint of improving peak workload during exercise...
21:34 , Feb 28, 2018 |  BC Extra  |  Financial News

Celgene's slide continues after refusal to file letter

Celgene Corp. (NASDAQ:CELG) shed $8.66 to $87.12 on Wednesday after FDA issued a refusal to file letter for an NDA for ozanimod (RPC1063) to treat multiple sclerosis. The news was announced after market close Tuesday...
20:26 , Feb 2, 2018 |  BC Week In Review  |  Company News

EPO revokes Forward patent related to Tecfidera

Forward Pharma A/S (NASDAQ:FWP) said the European Patent Office revoked Forward's European Patent No. EP2801355, which Forward claims is infringed by blockbuster multiple sclerosis drug Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB). The company told...
23:36 , Jan 29, 2018 |  BC Extra  |  Company News

EPO revokes Forward patent related to Tecfidera

Forward Pharma A/S (NASDAQ:FWP) lost $1.49 (28%) to $3.87 on Monday after the European Patent Office revoked Forward's European Patent No. EP2801355, which Forward claims is infringed by blockbuster multiple sclerosis drug Tecfidera dimethyl fumarate...
22:17 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Reata reports Phase Ib data for omaveloxolone in melanoma

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported interim data from 30 evaluable patients with unresectable or metastatic melanoma in the Phase Ib portion of the Phase Ib/II REVEAL trial showing that omaveloxolone (oral RTA 408) plus Yervoy...
20:04 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

Designing specificity

Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform yielded an antagonist with selectivity for OX1R over OX2R and disclosed data for the compound in...
00:03 , Dec 1, 2017 |  BC Week In Review  |  Company News

Biogen gains MS candidate from Alkermes

On Nov. 27, Biogen Inc. (NASDAQ:BIIB) obtained an exclusive, worldwide license to commercialize multiple sclerosis candidate ALKS 8700 from Alkermes plc (NASDAQ:ALKS), removing a potential competitor to Biogen’s blockbuster MS drug Tecfidera dimethyl fumarate and...